Papers

2024 · J Rheumatol

Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 Study

Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Alexeeva E, Appenzeller S, et al.

J Rheumatol August 2024, 2024-0298

PubMed

2024 · J Autoimmun

The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C

Caorsi R, Consolaro A, Speziani C, Sozeri B, Ulu K, Faugier-Fuentes E, et al.

J Autoimmun Volume 147, July 2024, 103265

Related project: The HyperPED-COVID Registry

PubMed

2024 · Ann Rheum Dis

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G, et al.

Ann Rheum Dis [Epub ahead of print]

Related project: Liaisons with pharmaceutical companies

PubMed

2024 · J Clin Immunol

Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry

Vyzhga Y, Frenkel J, Insalaco A, Anton J, Kone-Paut I, Legger GE, et al.

J Clin Immunol 2024 May 17;44(5):119

Related project: Eurofever

PubMed

2024 · Semin Arthritis Rheum

Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry

Mastrolia MV, Matucci-Cerinic C, Ozen S, Kasapcopur O, Gaggiano C, Kone-Paut I, et al.

Semin Arthritis Rheum June 2024, 66:152454

Related project: Eurofever

PubMed

2024 · Rheumatology (Oxford)

Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry

Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, et al.

Rheumatology (Oxford) [Epub ahead of print]

Related project: PharmaChild

PubMed

2024 · Rheumatology (Oxford)

Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis

Vojinovic J, Foeldvari I, Dehoorne J, Panaviene V, Susic G, Horneff G, et al.

Rheumatology (Oxford) January 2024; 63(1):140-148

Related project: Liaisons with pharmaceutical companies

PubMed

2023 · Rheumatology (Oxford)

Validation of the PEDiatric Behcet's Disease classification criteria: an evidence-based approach

Matucci-Cerinic C, Helene P, Sulaiman AM, Brogan PA, Cantarini L, Gul A, et al.

Rheumatology (Oxford) [Epub ahead of print]

Related project: Eurofever

PubMed

2023 · Rheumatology (Oxford)

Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way

Backstrom M, Tarkiainen M, Gottlieb BS, Trincianti C, Qiu T, Morgan E, et al.

Rheumatology (Oxford) 2023 Oct 3;62(10):3421-3426

PubMed

2023 · J Rheumatol

Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials

Ruperto N, Lovell DJ, Berman A, Anton J, Viola DO, Lauwerys B, et al.

J Rheumatol November 2023, 50(11):1471-1480

Related project: Liaisons with pharmaceutical companies

PubMed

2023 · Clin Exp Rheumatol

TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome

Gerritsma AM, Sutera D, Cantarini L, Cattalini M, Lachmann HJ, Minden K, et al.

Clin Exp Rheumatol. 2023 Oct;41(10):1998-2007

Related project: Eurofever

PubMed

2023 · Orphanet J Rare Dis

Breaking down the fences among registries on autoinflammatory diseases: the E-Merge project

Vyzhga Y, Hentgen V, Caorsi R, Wittkowski H, Hofer M, Ruperto N, et al.

Orphanet J Rare Dis 2023 Jul 17;18(1):191

Related project: Eurofever

PubMed

2023 · The Lancet

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutova S, et al.

Lancet Aug 12;402(10401):555-570

Related project: Liaisons with pharmaceutical companies

PubMed

2023 · Arthritis Care Res

Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept

Brunner HI, Tzaribachev N, Louw I, Calvo Penades I, Avila-Zapata F, Horneff G, et al.

Arthritis Care Res Vol. 75, No. 11, November 2023, pp 2259-2266

Related project: Liaisons with pharmaceutical companies

PubMed

2023 · Rheumatology (Oxford)

Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles

Kim H, Saygin D, Douglas C, Wilkerson J, Erman B, Pistorio A, et al.

Rheumatology 2023 Nov 2;62(11):3680-3689

PubMed

2023 · Pediatr Rheumatol Online J

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry

van Straalen JW, Baas L, Giancane G, Grebenkina L, Brunner J, Vega-Cornejo G, et al.

Pediatr Rheumatol Online J 2023 Feb 21;21(1):19

Related project: PharmaChild

PubMed

2023 · Arthritis Care Res

Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study

Ruperto N, Lovell DJ, Berman A, Avila-Zapata F, Horneff G, Alessio M, et al.

Arthritis Care Res 2023 Aug;75(8):1804-1814

Related project: Liaisons with pharmaceutical companies

PubMed

2023 · Ann Rheum Dis

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, et al.

Ann Rheum Dis 2023 Jan;82(1):154-160

Related project: Liaisons with pharmaceutical companies

PubMed

2023 · Arthritis Rheumatol

Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis

van Straalen JW, Kearsley-Fleet L, Klotsche J, de Roock S, Minden K, Heiligenhaus A, et al.

Arthritis Rheumatol Vol. 75, No. 2, February 2023, pp 318-327

Related project: PharmaChild

PubMed

2023 · Arthritis Care Res

Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring

van Dijkhuizen EHP, Ridella F, Naddei R, Trincianti C, Avrusin I, Mazzoni M, et al.

Arthritis Care Res (Hoboken) Feb;75(2):391-400

Related project: EPOCA

PubMed

2022 · RMD Open

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis

Alongi A, Giancane G, Naddei R, Natoli V, Ridella F, Burrone M, et al.

RMD Open 2022 Mar;8(1):e002042

Related project: EPOCA

PubMed

2022 · Arthritis Rheumatol

Reply to the Letter to the Editor by Kimura et al "Response to Editorial Accompanying STOP-JIA Articles by Ruperto et al"

Ruperto N, Martini A, Pistorio A for the Paediatric Rheumatology International Trials Organisation (PRINTO)

Arthritis Rheumatol 2022 May;74(5):913-914

PubMed

2022 · J Rheumatol

Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the Pharmachild registry

Giancane G, Papa R, Vastert S, Bagnasco F, Swart JF, Quartier P, et al.

J Rheumatol 2022;49:398-407

Related project: PharmaChild

PubMed

2022 · Rheumatology (Oxford)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use

van Straalen JW, Krol RM, Giancane G, Panaviene V, Ailioaie LM, Dolezalova P, et al.

Rheumatology (Oxford) 2022 May 5;61(5):2104-2112

Related project: PharmaChild

PubMed